Mirion Technologies, Inc.

Mirion Technologies, Inc. (MIR) Market Cap

Mirion Technologies, Inc. has a market capitalization of $4.81B.

Financials based on reported quarter end 2025-12-31

Price: $19.66

0.09 (0.46%)

Market Cap: 4.81B

NYSE · time unavailable

CEO: Thomas D. Logan

Sector: Industrials

Industry: Industrial - Machinery

IPO Date: 2020-08-20

Website: https://www.mirion.com

Mirion Technologies, Inc. (MIR) - Company Information

Market Cap: 4.81B · Sector: Industrials

Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, and Japan. It operates through two segments, Medical and Industrial. The medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products. This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation. The Industrial segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.

Analyst Sentiment

79%
Strong Buy

Based on 8 ratings

Analyst 1Y Forecast: $28.80

Average target (based on 2 sources)

Consensus Price Target

Low

$27

Median

$29

High

$29

Average

$29

Potential Upside: 45.0%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 MIRION TECHNOLOGIES INC CLASS A (MIR) — Investment Overview

🧩 Business Model Overview

Mirion Technologies Inc. (Class A; ticker: MIR) operates as a technology platform focused on radiation detection, measurement, and monitoring solutions. The company provides sophisticated devices, systems, and software that address critical applications across a diverse set of end-markets, including nuclear power, defense, medical, research, and industrial sectors. Mirion’s business is rooted in engineering and manufacturing highly specialized equipment that ensures the safety, accuracy, and efficiency of radiological operations. The company supports customers through product sales, recurring service agreements, and through long-term support contracts, aiming to serve as a trusted partner in applications where radiation exposure or measurement is essential. The business model is built on supplying mission-critical products that often operate in highly regulated and technically demanding environments, driving enduring customer relationships and high switching costs.

💰 Revenue Streams & Monetisation Model

Mirion Technologies generates revenue from multiple, complementary streams. The primary source is the sale of proprietary equipment such as radiation detectors, dosimeters, imaging solutions, and analytical instruments. These products are often tailored to meet specific customer standards and regulatory demands. Service-based revenues constitute a significant portion of the mix, stemming from equipment maintenance, calibration, training, and regulatory compliance consulting. Software licensing and upgrades represent a growing category, notably in sectors with digitization and real-time monitoring needs. The company also benefits from long-dated contracts, particularly in the nuclear and defense verticals, providing visibility and stability to its revenue base. In medical applications, Mirion enables advanced diagnostics and therapeutic procedures, further diversifying its monetisation through healthcare partnerships and recurring business stemming from consumables or periodic system updates.

🧠 Competitive Advantages & Market Positioning

Mirion’s competitive advantages are deeply embedded in its heritage of technical excellence, comprehensive product breadth, and entrenched relationships within highly regulated markets. The company is a recognized leader in radiation safety and measurement, with a substantial installed base, particularly in nuclear energy, which requires high reliability and rigorous certifications. Mirion’s integrated solutions portfolio — covering hardware, software, and services — creates switching costs, discouraging customers from transitioning to alternative suppliers. The company’s operational presence in both North America and Europe positions it to serve global blue-chip customers and to respond to regionally nuanced regulatory requirements. Mirion frequently participates in long buying cycles typical of the nuclear and defense sectors, and its expertise in compliance and project delivery underpins its reputation and barriers to entry against less established competitors. Continuous investment in R&D ensures its solutions remain at the forefront of industry standards, while selective M&A has enabled Mirion to extend its capabilities into adjacent verticals.

🚀 Multi-Year Growth Drivers

Several secular and industry-specific trends underpin the growth prospects for Mirion Technologies. A significant driver is the ongoing global need for nuclear power generation as a reliable, low-carbon energy source. The construction of new reactors, plant life extensions, and heightened regulatory scrutiny all necessitate the sophisticated monitoring solutions that Mirion provides. In the medical field, the growth in advanced diagnostic imaging and adoption of radiation-based therapy are expanding applications for Mirion’s technology. Heightened global security concerns support continued investment in defense-related radiation detection and threat monitoring infrastructure. Regulatory evolution worldwide emphasizes worker and public safety in radiological environments, further reinforcing demand for best-in-class dosimetry and detection equipment. Additionally, recurring revenue from service agreements, digital monitoring, and lifecycle support enhances predictability and fosters margin expansion. Mirion’s potential for bolt-on acquisitions and penetration into emerging markets serves as an additional vector for long-term compounding.

⚠ Risk Factors to Monitor

Investors should monitor a range of external and company-specific risk factors. The regulated nature of key end-markets such as nuclear and medical implies lengthy procurement processes and potential delays from regulatory changes or policy shifts. Any reduction in government or utility capital expenditure — for instance, from budget cycles or shifts in energy policy — can impact order timing and volume. Medical imaging and life sciences markets, while growing, face their own reimbursement and regulatory dynamics that can affect technology adoption rates. Competition remains a risk, particularly with advances in non-ionizing imaging or alternative diagnostic technologies. Supply chain disruptions, inflationary input costs, or geopolitical tensions may impact manufacturing operations or delivery schedules. Ongoing integration risk from acquisitions, as well as the possibility of disruptive technological change, are additional considerations that could affect long-term performance.

📊 Valuation & Market View

Mirion is generally evaluated by investors as a specialized industrial technology business with elements of critical infrastructure and healthcare technology exposure. The company typically trades at valuation multiples reflecting its balance of cyclical exposure and recurring revenue streams. Factors that influence its valuation include its installed base, visibility from long-term contracts, and potential for margin expansion via service and software offerings. The investment community often benchmarks MIR against peers in industrial instrumentation, healthcare equipment, and defense technology solutions, recognizing its niche position within radiation safety markets. Upside levers in valuation may arise from successful integration of acquisitions, outperformance in growth geographies, or step-changes in regulatory standards that accelerate demand. As with similar complex engineered product businesses, Mirion’s valuation can be sensitive to macroeconomic shifts, project procurement cycles, and sector rotation between growth and safety-oriented equities.

🔍 Investment Takeaway

Mirion Technologies represents a unique opportunity in the intersection of critical infrastructure, healthcare, and security, underpinned by robust regulatory demand and a leading position in niche markets. Its business offers resilience via long-term contracts, servicing arrangements, and a broad array of proprietary technologies. Secular trends, including the expansion of nuclear energy, rising medical imaging utility, and increased focus on radiation safety, collectively support a positive long-term outlook. Risk management is key, given regulatory, cyclical, and execution-related uncertainties inherent to Mirion’s diverse end-markets. For investors seeking exposure to a specialized industrial and healthcare technology platform with embedded secular tailwinds and recurring revenue characteristics, Mirion Technologies merits careful consideration as a component of a diversified, future-oriented portfolio.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"MIR reported revenue of $277.4M and net income of $17.3M for the year ending December 31, 2025. The company has shown strong revenue growth and profitability metrics, leading to an EPS of $0.07. MIR has total assets of $3.588B against total liabilities of $1.671B, resulting in a favorable equity position of $1.917B. The cash flow from operations stands at $76.1M, indicating solid operational efficiency. Free cash flow is a healthy $66.3M, underscoring its ability to generate cash. The stock price is currently $19.25, reflecting a 24.51% increase over the past year, which is significant despite recent volatility of a -21.75% change over the last six months. MIR offers a price consensus target of $29, indicating potential for price appreciation. The lack of dividends does not detract from shareholder returns, as price appreciation is notable. Overall, the company's fundamentals demonstrate a resilient growth profile."

Revenue Growth

Good

Strong revenue growth indicated by $277.4M.

Profitability

Positive

Net income of $17.3M reflects good profitability.

Cash Flow Quality

Good

Healthy operating and free cash flow metrics.

Leverage & Balance Sheet

Positive

Solid balance sheet with total equity of $1.917B.

Shareholder Returns

Good

Significant 1-year price appreciation of 24.51%.

Analyst Sentiment & Valuation

Positive

Price target of $29 suggests upside potential.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management’s tone is confident on nuclear momentum and 2026 execution, repeatedly stressing record order intake and a >$400M large-opportunity pipeline. They also highlight strong cash generation (2025 FCF $131M, 57% conversion) and self-help (nearly +100 bps from procurement), plus AI as an efficiency lever. However, the Q&A reveals the pressure points: (1) Q1 2026 is explicitly the “lightest quarter” with margin contraction due to Paragon dilution and seasonality; (2) medical recovery is expected but management hedges that more color will come after Q1, acknowledging front-half strength from China shipments in 2025; (3) margin trajectory to 30%+ by 2028 is not guaranteed—tariffs and near-term Paragon dilution are called out as headwinds. Analyst concerns focused on whether pipeline growth should mechanically translate into backlog growth and on the sustainability of incremental margins; management answered with gating/timing uncertainty and a range of offsetting forces rather than a straight-up margin story.

AI IconGrowth Catalysts

  • Nuclear power strength: nuclear power organic revenue up >11% in 2025; expected double-digit organic growth into 2026
  • Large opportunity pipeline supporting 2026: right to win on >$400M large projects in 2026 (incl. $200M carryover from 2025)
  • Installed-base monetization: ~80% of nuclear revenue from the installed base via life extension/operate/modernize

Business Development

  • Acquired CERTREC (July 2025) to increase North American nuclear power exposure
  • Closed acquisition of Paragon Energy Solutions (December 2025); Paragon expected ~25%+ growth in 2026
  • Contractual commitments with >20 SMR developers (for legacy Mirion solutions); improved traction/‘drag alarm’ activity tied to Paragon & CERTREC
  • SMR-related orders: $39M in 2025 vs $17M combined in 2023-2024
  • Large Q4 awards included $55M Asia installed base order (disclosed in prior October call)

AI IconFinancial Highlights

  • Q4 enterprise revenue: $277.4M (+9% YoY); organic growth +0.5% (hit by tough comps)
  • FX contributed +3.4% to Q4 growth (noted ~36% of 2025 revenue euro-denominated)
  • Q4 adjusted EBITDA: $77.6M (+11.5% YoY); adjusted EBITDA margins expanded +60 bps (despite Paragon dilutive impact for December)
  • Full-year adjusted EBITDA margin expansion: +90 bps (procurement/operating leverage partially offset by tariff impact and Paragon dilution)
  • Full-year revenue: $925.4M (+7.5% YoY)
  • Full-year adjusted EPS: $0.46 (+12% YoY) but slightly below 2025 guidance range ($0.48-$0.52) due to tax dynamics
  • Adjusted free cash flow (FCF): 2025 $131M (~2x 2024) with 57% conversion; beat guidance
  • 2026 guidance: total revenue +22% to +24%; adjusted EBITDA $285M-$300M with margins 25%-26% (~+90 bps expansion expected)
  • 2026 adjusted EPS: $0.50-$0.57 (includes stock-based comp); midpoint would be ~$0.61 or ~$0.07 higher ex stock-based comp
  • Q1 2026 expected as lightest quarter for revenue and adjusted EBITDA; Q1 enterprise EBITDA margins expected to contract vs Q1 2025 (Paragon dilutive impact)

AI IconCapital Funding

  • Reduced term loan B: $695M -> $450M; refinanced down to SOFR +200
  • Issued two convertible notes at 0.250% coupons in 2025
  • 2026 guidance includes ~275M fully diluted shares reflecting full-year impact of September 2025 capital raise
  • No explicit buyback/debt outstanding totals beyond term loan B reduction are provided in the transcript

AI IconStrategy & Ops

  • Synergy focus in 2026 beyond foundational integration (finance/HR/IT): commercial integration, improved pricing heuristics, and supply chain optimization
  • Supply chain/procurement self-help delivered nearly +100 bps adjusted EBITDA margin improvement in 2025 (procurement process improvement in legacy Mirion)
  • AI productivity push: launched 17 internal bespoke AI applications in 2025; another ~7 in development; hired inaugural Chief AI & Digital

AI IconMarket Outlook

  • 2026 revenue growth guided at +22% to +24% (FX and acquisitions contribute; organic guidance otherwise implied 5%-7% absent tailwinds)
  • 2026 adjusted free cash flow: $155M-$175M
  • 2026 adjusted EBITDA margins: 25%-26% (management emphasized margin expansion not ‘guaranteed’ to 30%+ by 2028 due to headwinds)
  • Q1 2026 organic revenue growth expected low single digits; medical organic mid-single digits; nuclear & safety likely flat
  • Nuclear & safety Q1: sensing business volume lower due to tough 2025 project timing comp affecting both revenue and margins

AI IconRisks & Headwinds

  • Organic headwinds in 2025: organic headwinds ~250 bps from US government shutdown and DOGE initiatives impacting labs/research end market
  • Labs business affected by 43-day government shutdown (delay expected, not decline; normalization expected to take time)
  • RTQA sluggish in 2025 tied to hardware headwinds in North America, China, and Japan; also tough comps due to prior-year strength
  • Medical segment headwinds in 2025: tough comps (nuclear medicine up 31% in Q4 2024; dosimetry up 14% in Q4 2024); RTQA down due to Asia/Europe hardware headwinds
  • Paragon acquisition dilutive impact on margins (Q4 margin decline and ongoing 2026 margin dilution, especially in Q1); management expects return to margin expansion in back half of year
  • Tariff impact cited as partially offsetting margin expansion in 2025, and acknowledged as a headwind to reaching higher margin targets; no specific mitigation steps are detailed beyond procurement/operating leverage/self-help/AI narrative
  • Large project timing remains a ‘dynamic target’; management avoids committing to a tight correlation between pipeline and backlog growth due to gates/complexity

Sentiment: MIXED

Note: This summary was synthesized by AI from the MIR Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (MIR)

© 2026 Stock Market Info — Mirion Technologies, Inc. (MIR) Financial Profile